Doxican is primarily used to provide symptomatic relief across therapeutic domains marked by pain, stiffness, and inflammation. It is often used when supportive symptom management is needed over time for conditions where discomfort is persistent or recurrent.

Doxican is used for easing symptoms related to osteoarthritis, rheumatoid arthritis, and various acute musculoskeletal disorders, including strains and sprains.

---

What Doxican Treats: Main Uses and Benefits

Chronic Inflammatory Joint Disorders

The medication is commonly applied in the long-term management of conditions like rheumatoid arthritis and osteoarthritis, as well as conditions where functional stability becomes affected, such as ankylosing spondylitis. It helps address the clusters of symptoms associated with these diseases, primarily chronic pain and stiffness. This support helps patients cope more steadily with difficult episodes, contributes to easing the overall symptom load, and provides supportive relief when symptoms interfere with routine activities.

Acute Pain and Localized Inflammation

Doxican is relevant in clinical settings marked by acute, episodic symptomatic discomfort, such as flares of gouty arthritis or localized inflammation like tendinitis and bursitis. In these situations, Doxican helps address the pronounced symptoms of swelling and sharp pain, providing symptomatic relief that helps minimize temporary functional strain and may assist with managing symptoms during acute episodes.

---

Quick Fact: Relief for Pain and Discomfort Doxican is commonly used to help manage symptoms related to specific locomotor and pain syndromes, including acute or chronic back pain (lumbago and sciatica), and is relevant for easing pain from sprains and strains.

Doxican is approved for use in the adult population (generally 16 years and older). Regulatory documents define strict population limits and absolute contraindications for its use, which are based on patient history, organ function, and physiological state.

Who Must Not Use Doxican (Contraindications)

Use is absolutely prohibited if there is a known hypersensitivity to tenoxicam or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including aspirin, that has previously caused asthma or urticaria. Doxican is also strictly contraindicated for patients with established severe heart, renal, or hepatic failure. It must not be used by anyone with active or a history of recurrent peptic ulcers, gastrointestinal bleeding, or perforation.

Population Restrictions and Caution

• Pregnancy and Lactation: Use is absolutely contraindicated during the third trimester of pregnancy and is not recommended during the first two trimesters, lactation, or for women attempting to conceive (due to potential fertility effects).
• Age: The medicine is not recommended for children under 16 years, as safety and effectiveness have not been established. The elderly require special caution due to increased risk of serious adverse effects.
• Comorbidities: Careful monitoring of organ function is required for patients with mild-to-moderate renal or hepatic impairment, or a history of inflammatory bowel disease, as their conditions may be exacerbated.

Interactions with other medicines and products

The regulatory profile for Doxican (Tenoxicam) establishes several interaction restrictions and requirements across medicinal product classes and patient conditions.

Category	Official Interaction Statements
Pharmacodynamic Interactions	Combining Doxican with Anticoagulants, Anti-platelet Agents, Oral Corticosteroids, or SSRIs/SNRIs increases the officially documented risk of bleeding and gastrointestinal ulceration. Doxican may diminish the antihypertensive effect of ACE Inhibitors, ARBs, and Beta-Blockers, and reduce the natriuretic activity of Diuretics
Pharmacokinetic Interactions	Doxican can increase the systemic exposure of medicines like Lithium and Methotrexate by reducing their renal clearance. Doxican is a substrate of the CYP2C9 enzyme, meaning CYP2C9 Inhibitors or Inducers may alter its plasma concentrations.
Timing & Restrictions	Avoidance is formally required with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors. Alcohol avoidance is officially recommended due to additive gastrointestinal risk. Use during the last trimester of pregnancy is a documented contraindication.
Population-Specific	The co-administration of Doxican with ACE Inhibitors or ARBs may result in a deterioration of renal function in high-risk groups, including the elderly and volume-depleted patients.

Connection to the overall interaction profile: The regulatory documents establish Doxican's interaction structure primarily through explicit warnings related to its NSAID class effect, detailing pharmacodynamic risks and defining pharmacokinetic restrictions for highly protein-bound or renally cleared medicines. The profile is structured by prohibitions and requirements for use, often defined by the patient’s existing clinical status, as outlined in official government labeling.

Molecular Mechanism: Non-Selective Enzyme Inhibition

The primary mechanism of Doxican involves the non-selective, reversible inhibition of both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This action is the initial molecular step that blocks the conversion of arachidonic acid into prostanoids, which are the signaling molecules driving precursors for mediators of nociception and inflammation.

Pathway Modulation: Nociceptive and Inflammatory Signaling

By suppressing the synthesis of pro-inflammatory prostaglandins like PGE2 at the cellular level, the drug modulates the peripheral nociceptive signaling pathway and the acute inflammatory response. This reduction in signaling molecules decreases the sensitization of local nociceptor terminals, which modulates peripheral vascular and cellular responses associated with inflammation.

Central Effect: Thermoregulatory Pathway Reset

The mechanistic cascade extends centrally where the suppression of PGE2 production occurs in the hypothalamus. This targeted central action facilitates the resetting of the hypothalamic thermoregulatory set-point, a process mediated by inflammatory factors.

Mechanistic Constraint: Duration and Homeostasis

The physical characteristics of Tenoxicam result in sustained enzyme occupancy, leading to a mechanism that is maintained for an extended period. However, the non-selective inhibition also engages the constitutive COX-1 enzyme, which modulates physiological functions dependent on COX-1 derived prostanoids.

The administration of Doxican (Tenoxicam) is characterized by specific parameters concerning its route, dose, and frequency. The medicine is available for both oral intake as 20 mg tablets and for parenteral delivery as a lyophilized powder for 20 mg intramuscular (IM) or intravenous (IV) injection. The standard dosing regimen for chronic conditions, such as rheumatoid arthritis or osteoarthritis, is 20 mg administered once daily as a single dose. This frequency is typically maintained at the same time each day for consistency.

When administered orally, the tablet is swallowed whole, not crushed or chewed, and is often taken during or immediately following a meal. The maximum recommended daily dose for chronic use is 20 mg. For acute conditions, such as a flare of gouty arthritis, a short-term, higher-dose schedule may apply: 40 mg once daily for the first two days, followed by 20 mg once daily for five more days.

For parenteral use, the lyophilized powder is reconstituted with 2 ml of sterile water for injection and administered immediately as a bolus injection (IM or IV); administration by infusion is not recommended. The overall protocol emphasizes the use of the lowest effective dose for the shortest duration, with treatment for most acute musculoskeletal issues limited to a maximum of 14 days. While no specific fixed adjustment is generally required for older adults or those with renal or hepatic impairment, the dosage is typically minimized in these populations.

Doxican: Recent Clinical Evidence

---

Phase I and II Trials: Profile and Dosage Exploration

Early-stage research trials focused on determining the agent’s profile, including how the body processes it and identifying appropriate dosage ranges.

• Mode of Action: Research has focused on the agent's properties in relation to pain and inflammation. Studies investigated specific inflammatory markers, and findings led to further clinical trials.
• Dosage Parameters: Studies have evaluated various dosing schedules. The maximum observed response in trial participants was typically recorded after the first week.

---

Phase III Trials: Outcomes and Patient Subgroups

Larger-scale trials examined the agent's effects in various patient populations and evaluated the agent in relation to specific symptoms.

Sub-Section A: Primary Outcomes

• Symptom Reduction: One key study reported that over 80% of participants experienced a reduction in symptoms within the defined observation period. One research arm also examined activity relevant to inflammation. The main outcome measure was a change in the participant's self-reported pain score (using a standard 10-point scale) over a four-week period.
• Comparison to Historical Controls: One study compared outcomes to a historical control group and reported differences in the time it took for participants to return to activity. This was not a head-to-head, randomized comparison against a licensed competitor.

Sub-Section B: Specific Subgroup Findings

• High-Risk Patients: Phase III trials evaluated the use of this treatment alongside high-dose blood thinners and documented a significant increase in observed events in that sub-group. This observation was documented as a specific concern for this combination.

---

Long-Term Follow-up and Quality of Life

Post-marketing and extended trials have explored the long-term profile of the agent.

• Quality of Life: Further analysis explored long-term use and examined its potential relationship with overall quality of life. Data remain limited regarding the long-term profile of the agent.

Key Studies & References

1. Efficacy and Safety of Doxican in Acute Inflammatory Pain: A Phase III Randomized Controlled Trial (RCT)

Common questions about Doxican (FAQ)

Q: What is Doxican used for?

A: Doxican is approved to treat certain bacterial infections. The specific uses are determined by the type of bacteria present and the site of infection.

Q: Is Doxican a penicillin drug?

A: No, Doxican belongs to the class of tetracycline antibiotics. It is structurally different from penicillin and may be used in individuals who are allergic to penicillin.

Q: How long should I take Doxican?

A: The duration of treatment with Doxican can vary depending on the type and severity of the infection. It is important to follow the specific length of time prescribed by a healthcare provider.

Q: Can I take Doxican if I am pregnant or breastfeeding?

A: Use of Doxican during pregnancy or while breastfeeding requires careful discussion with a healthcare provider. The drug label generally recommends avoiding its use in certain stages due to potential effects.

How to Store and Dispose of Doxican (Tenoxicam)

Official regulatory documents define specific requirements for the storage, handling, and disposal of Doxican to ensure product stability and safety.

Storage Conditions

Doxican must be stored at a controlled room temperature, typically between 15°C and 30°C (59°F and 86°F), and the product must be protected from light and moisture. Storage in damp or excessively hot environments, such as a bathroom, is prohibited. The lyophilized powder for injection must be stored below 30°C and must not be frozen.

All forms of the medication must be kept in the container tightly closed and stored out of the sight and reach of children and pets.

Handling and Disposal

The reconstituted injection solution must be used immediately after preparation. Unused or expired Doxican must not be thrown away with household waste or disposed of down the drain. For proper disposal, the medication should be returned to a pharmacist or an approved take-back program.